Navidea Biopharmaceuticals Announces Enrollment of First Subject in...

... emission tomography (PET) scan findings have the ability to distinguish subjects with MCI who progress to Alzheimer's disease (AD) from those who do not. Enrollment is currently planned at approximately five sites throughout the U.S. The first ...

http://www.biospace.com/news_story.aspx?StoryID=291736&full=1